Prices are checked against each store and labelled with when.
It checks today's price at every store, compares the alternatives and answers in about a minute.
Compounded tirzepatide is a once-weekly injectable that acts on both GLP-1 and GIP receptors, the same dual mechanism as brand-name tirzepatide (Mounjaro, Zepbound). This version adds glycine to the formulation and is sold as a physician-supervised program with gradual dose titration and provider check-ins. It suits adults seeking medical weight management who want a structured, monitored plan rather than a standalone vial. Compared with semaglutide-only options, the dual agonist approach is generally associated with greater average weight loss in trials of the branded drug, though compounded versions are not FDA-approved and vary by pharmacy.
In stockReturn policy
Injectable Tirzepatide is a once-weekly medication used as part of a physician-supervised weight management program. Tirzepatide belongs to a class of medications known as GLP-1 and GIP receptor agonists, which influence hormones involved in appetite regulation and metabolic signaling. This compounded formulation combines Tirzepatide with glycine.
It influences hormones involved in appetite signaling and helps regulate glucose metabolism after meals. It also slows gastric emptying, which may promote feelings of fullness. It is meant to be used alongside nutrition and lifestyle changes.
A licensed medical provider monitors the treatment plan. The plan is structured for gradual titration, and the provider may adjust the dose based on response and tolerance.